Diabetes :: New IDF guidelines raise importance of post-meal glucose control

The International Diabetes Federation (IDF) has published new guidelines on the contribution and impact of post-meal glucose in diabetes disease management at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD) on September_19, 2007. The IDF recognises the growing evidence that post-meal glucose is a key contributor to overall glycaemic control – particularly with respect to HbA1C levels, and that reducing post-meal glucose has a significant impact on the risk of developing diabetic complications.

Diabetes :: New study uncovers potential role of leptin in diabetes

A new Joslin-led study has shown that leptin, a hormone known mainly for regulating appetite control and energy metabolism, plays a major role in islet cell growth and insulin secretion. This finding opens up new avenues for studying leptin and its role in islet cell biology, which may lead to new treatments for diabetes.

Sleep :: Lack of sleep doubles risk of death… but so can too much sleep

Researchers from the University of Warwick, and University College London, have found that lack of sleep can more than double the risk of death from cardiovascular disease. However they have also found that point comes when too much sleep can also more than double the risk of death.

Liver :: Quick-burning carbs may cause fatty liver

The obesity epidemic has spawned not just diabetes, but another serious public health problem: a surge in fatty liver disease, which can lead to cirrhosis and liver failure. Now, research suggests that limiting consumption of high-glycemic-index carbohydrates can prevent the condition in mice. A clinical trial is now testing this idea in overweight adolescents, as well as the possibility of reversing fatty liver disease through diet.

Diabetes :: ACTOS is associated with a 38 percent lower risk of heart attack

New research, including two studies presented this week at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD), further support the cardiovascular safety of ACTOS (pioglitazone HCI) and its benefits regarding improved blood glucose and blood lipid levels for patients with type 2 diabetes.